355 ALHAMBRA CIRCLE, CORAL GABLES, FL
Reports Third Quarter 2025 Financial Results and Provides Business Update
Announces $200 Million Share Repurchase Program
Amended material disclosure
Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer
Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
Appoints Daniel Curran, MD, to its Board of Directors
Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence